STAT3 and neoplasm: A Phase II trial of ruxolitinib in triple-negative breast cancer confirmed inhibition of STAT3 activation in patient tumor samples; however, no clinical response was observed, as evaluated by the RECIST criteria, and the study was terminated (NCT01562873)[92,93].